# **Major Resources Table**

In order to allow validation and replication of experiments, all essential research materials listed in the Methods should be included in the Major Resources Table below. Authors are encouraged to use public repositories for protocols, data, code, and other materials and provide persistent identifiers and/or links to repositories when available. Authors may add or delete rows as needed.

## Animals (in vivo studies)

Species	Vendor or Source	Background Strain	Sex	Persistent ID / URL
Mouse	The Jackson	C57BL/6J	M, F	https://www.jax.org/strain/000664
	Laboratory			
Mouse	The Jackson	C57BL/6:129SVJ	M, F	Details below in Genetically
	Laboratory			Modified Animals

# **Genetically Modified Animals**

	Species	Vendor or	Background	Other	Persistent ID / URL
		Source	Strain	Information	
Parent	Mouse	The Jackson	C57BL/6:129SVJ	Myh6-	https://www.jax.org/strain/005657
		Laboratory		merCremer	
Parent	Mouse	The Jackson	C57BL/6:129SVJ	MADM-ML-	https://www.jax.org/strain/030578
		Laboratory		11 <sup>GT/TG</sup>	

### **Antibodies**

Target antigen	Vendor or Source	Catalog #	Working concentrati on	Lot # (preferr ed but not required )	Persistent ID / URL
Picro- Sirius Red	Abcam	ab1506 81	Details in Protocol: Picro Sirius Red Stain Kit		https://www.abcam.com/picro-sirius-red-stain-kit-connective-tissue-stain-ab150681.html
Wheat Germ Agglutini n	Life Technologi es	W11261 W32466	1:100		https://www.thermofisher.com/order/catalog/product /W11261
EdU	Life Technologi es	C10337	Details in Protocol: Click-IT EdU Cell Proliferatio n Kit for Imaging		https://www.thermofisher.com/order/catalog/product /C10337
α- sarcomer ic actin	Sigma	A2172	1:500		https://www.sigmaaldrich.com/US/en/product/sigma/a2172
Ki67	Abcam	ab1558 0	1:300		https://www.abcam.com/ki67-antibody-ab15580.html
рНЗ	Millipore	06-570	1:300		https://www.emdmillipore.com/US/en/product/Anti- phospho-Histone-H3-Ser10-Antibody-Mitosis- Marker,MM_NF-06-570

DAPI	Millipore	268298	1:1000	https://www.emdmillipore.com/US/en/product/DAPI- Dihydrochloride-CAS-28718-90-3- Calbiochem,EMD_BIO-268298
CD31	R&D Systems	AF3628	1:30	https://www.rndsystems.com/products/mouse-rat-cd31-pecam-1-antibody_af3628
α- smooth muscle actin	Abcam	ab5694	1:100	https://www.abcam.com/alpha-smooth-muscle-actin-antibody-ab5694.html
CD45	R&D Systems	AF114	1:100	https://www.rndsystems.com/products/mouse-cd45-antibody_af114
TUNEL	Promega	G3250	Details in Protocol: DeadEnd Fluorometri c TUNEL system	https://www.promega.com/products/cell-health-assays/apoptosis-assays/deadend-fluorometric-tunel-system/?catNum=G3250

## **DNA/cDNA Clones**

Clone Name	Sequence	Source / Repository	Persistent ID / URL
β2Μ	5'-	NIH National	https://ncbi.nlm.nih.gov/gene/
	ATGTGAGGCGGGTGGAACTG,	Library of Medicine,	
	5'-	NCBI	https://www.ncbi.nlm.nih.gov/tools/primer-
	CTCGGTGACCCTGGTCTTTCTG		blast/index.cgi?LINK_LOC=BlastHome
Periostin (Postn)	5'-	NIH National	https://ncbi.nlm.nih.gov/gene/
	TATGCTCTGCTGCTGTT,	Library of Medicine,	
	5'-	NCBI	https://www.ncbi.nlm.nih.gov/tools/primer-
	TTTCTTCCCGCAGATAGCAC		blast/index.cgi?LINK_LOC=BlastHome
Col1A1	5'-	NIH National	https://ncbi.nlm.nih.gov/gene/
	GCCAAGAAGACATCCCTGAA,	Library of Medicine,	
	5'-	NCBI	https://www.ncbi.nlm.nih.gov/tools/primer-
	GCCATTGTGGCAGATACAGA		blast/index.cgi?LINK_LOC=BlastHome
Col3A1	5'-	NIH National	https://ncbi.nlm.nih.gov/gene/
	AGAGGCTTTGATGGACGCAA,	Library of Medicine,	
	5'-	NCBI	https://www.ncbi.nlm.nih.gov/tools/primer-
	CCACCAGGACTGCCGTTATT		blast/index.cgi?LINK_LOC=BlastHome

# **Cultured Cells**

Name	Vendor or Source	Sex (F, M, or unknown)	Persistent ID / URL

# Data & Code Availability

Description	Source / Repository	Persistent ID / URL		
RNA Sequencing	GEO database	Accession number: GSE221168		
	(NIH NLM NCBI)	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221168		

# Other

Description	Source /	Persistent ID / URL
	Repository	

5-ethynyl-2'- deoxyuridine (EdU, drug administration)	Life Technologies, catalog# E10187	https://www.thermofisher.com/order/catalog/product/E10187
Tamoxifen (drug administration)	Sigma	https://www.sigmaaldrich.com/US/en/substance/tamoxifen3715110540291
Tamoxifen (TAM, for analysis in LC-MS)	Toronto Research Chemicals, catalog# T006077	https://www.trc-canada.com/product-detail/?T006077
(Z)-4- Hydroxytamoxifen (4OHTAM, for analysis in LC-MS)	Toronto Research Chemicals, catalog# H954757	https://www.trc-canada.com/product-detail/?H954757
miRNeasy Mini Kit	Qiagen, catalog# 217004	https://www.qiagen.com/us/products/discovery-and-translational- research/dna-rna-purification/rna-purification/mirna/mirneasy- kits?catno=217004

#### **ARRIVE GUIDELINES**

The ARRIVE guidelines (<a href="https://arriveguidelines.org/">https://arriveguidelines.org/</a>) are a checklist of recommendations to improve the reporting of research involving animals. Key elements of the study design should be included below to better enable readers to scrutinize the research adequately, evaluate its methodological rigor, and reproduce the methods or findings.

### **Study Design**

Groups	Sex	Age	Number (prior to experiment)	Number (after termination)	Littermates (Yes/No)	Other description
Group 1 (Control)	M, F	9-12 weeks old	32	32	No	Normoxia (20.9 oxygen)
Group 2	M, F	9-12 weeks old	44	44	No	Hypoxia (7% oxygen)
Group 3 (control)	М	9-12 weeks old	10	10	No	Normoxia, food restricted (20.9% oxygen)
Group 4	М	9-12 weeks old	15	10	No	Hypoxia (5% oxygen)

**Sample Size:** Please explain how the sample size was decided Please provide details of any a *prior* sample size calculation, if done.

Sample size was decided based on having a p≤0.05 and 80% power for analysis

### **Inclusion Criteria**

We included male and females in our primary groups 1 and 2. Group 3 was used to eliminate diet/weight-gain as an influencing factor in cardiomyocyte proliferation. Since the results of group 3 were similar to group 1, we decided to use group 1 as the primary control group and included males and females in group 1. Group 4 was used to test if lower oxygen (5%) would increase cardiomyocyte proliferation, but when we concluded that it rather decreased proliferation, we focused on studying group 2 as the primary treatment group to induce myocyte proliferation and included males and females in group 2.

#### **Exclusion Criteria**

Mice that died during hypoxia treatment were excluded from terminal studies and analysis. Mice only died in group 4 from severe hypoxia. We also excluded females from group 3 because the results in males showed no difference when compared to group 1. We excluded females from group 4 because the results in males showed reduced cardiomyocyte proliferation and animal survival, which was more detrimental to mice. Therefore, we focused on the analysis of group 1 vs. group 2 and included both sexes in these groups.

### Randomization

Animals were randomly divided into each group.

### **Blinding**

Investigators of this study were blinded to the treatment group of the animals, following tissue harvest. Investigators were unblinded after data analysis was completed.